Replacing the “Necessary Evil”: Recombinant Human Serum Albumin as a Chemically Stable Alternative to Polysorbates in Biopharmaceutical Formulation

Polysorbate 20 and polysorbate 80 have long been treated as default stabilizers in biopharmaceutical formulations. They are effective surfactants and, for many years, have been viewed as a practical solution to interfacial stress and aggregation. Over time, however, a growing body of evidence has shown that these excipients are not chemically inert.

Polysorbates undergo oxidative degradation and enzymatic hydrolysis in the presence of trace host cell proteins, generating insoluble fatty acids and reactive byproducts that can compromise shelf life and, in some cases, raise immunogenicity concerns. As biologics move toward higher concentrations and longer storage requirements, these limitations are becoming harder to ignore. This article explores why polysorbates behave the way they do and why recombinant human serum albumin is increasingly being evaluated as a more stable alternative.

The Polysorbate Failure Mechanism: A Chemical Liability

Polysorbates have been long regarded as inert formulation aids. However, post-2015 literature has definitively reclassified them as chemically reactive liabilities with intrinsic failure modes that exacerbated by modern manufacturing processes.

Enzymatic Hydrolysis: The Silent Degradation

The dominant failure mechanism in monoclonal antibody (mAb) formulations is enzymatic hydrolysis. Despite rigorous downstream purification (Protein A, IEX), trace levels of host cell lipases often co-purify with the drug substance.

• Culprits: Early investigations implicated Phospholipase B-Like 2 (PLBL2), but subsequent work identified lysosomal phospholipase A2 (LPLA2) and lipoprotein lipase (LPL) as primary contributors to polysorbate degradation (Hall et al., 2016). These enzymes remain catalytically active even at refrigerated temperatures (2–8 °C) and at sub-ppm concentrations.
• Mechanism: Lipases cleave the ester bond between the fatty acid chain and the polyoxyethylene sorbitan core, releasing free fatty acids (FFAs). PS80 primarily yields oleic acid, while PS20 releases lauric, myristic, and palmitic acids (Kishore et al., 2011).

• The Particle Cliff: Because FFAs exhibit poor aqueous solubility, they accumulate until a solubility threshold is exceeded, resulting in sudden precipitation of crystalline particles. This “particle cliff” often manifests late in stability studies, resulting in catastrophic batch failures after extended storage (12-24 months) (Saggu et al., 2015).

Oxidative Degradation

Concurrently, the polyoxyethylene (POE) chains of polysorbates undergo auto-oxidation triggered by light, heat, or transition metals.

• Radical Propagation: This radical-mediated chain reaction generates hydroperoxides, which decompose into reactive aldehydes (formaldehyde, acetaldehyde) and ketones (Kerwin, 2008).
• Collateral Damage: Unlike hydrolysis, which primarily affects the surfactant, oxidative byproducts are reactive toward the therapeutic protein itself. Peroxides oxidize susceptible amino acid residues, like methionine and tryptophan, while aldehydes form Schiff bases with primary amines, promoting covalent protein aggregation (Wang et al., 2011).

The Clinical Consequence: Immunogenicity

The degradation of polysorbates is not merely a quality control specification issue; it represents a direct threat to patient safety via immunogenicity.

Particulates as Unintended Adjuvants

The human immune system is evolutionarily tuned to recognize particulate matter as a “danger signal.”

• Mechanism: Insoluble fatty acid particles formed by polysorbate degradation can act as unintended adjuvants. When therapeutic proteins adsorb onto the particle surfaces, they are presented to antigen-presenting cells (APCs) in a repetitive, virus-like array (Singh, 2011).
• Breaking Tolerance: This particulate presentation can break B-cell tolerance, triggering the production of Anti-Drug Antibodies (ADAs). The historical Eprex® (erythropoietin) case serves as the definitive cautionary tale: Reformulation  removed of human serum albumin (HSA), which traditionally masked impurities and stabilized the protein, and introduced Polysorbate 80, which interacted with syringe components. This created excipient-driven micelles that functioned as an unintentional adjuvant, leading to a catastrophic loss of immune tolerance and the development of pure red cell aplasia (Boven et al., 2005).

Albumin as a Biological Stabilizer

Human serum albumin (HSA) is the body’s primary extracellular stabilizer, evolved to bind hydrophobic molecules and protect plasma proteins. Unlike polysorbates, which function solely through surface activity, albumin provides both chaperone-like stabilization and antioxidant protection.

The Chaperone Effect

Albumin functions as an extracellular chaperone, preventing protein aggregation through specific hydrophobic interactions.

• Surface Competition: Like polysorbates, albumin is amphiphilic and coats hydrophobic surfaces (air-liquid interfaces), preventing loss of the therapeutic protein from adsorption to these surfaces as well as degradation due to unfolding at these boundaries (Finn et al., 2012).
• Hydrophobic Shielding: Crucially, HSA possesses conserved hydrophobic binding pockets (Sudlow Sites I and II). When a therapeutic protein undergoes thermal or stress-induced partial unfolding, HSA binds reversibly to the exposed hydrophobic patches. This “capping” prevents the unfolded protein from associating with others to form aggregates, effectively arresting the nucleation of amyloid fibrils (Khan & Naeem, 2024).

Antioxidant Capacity: The Cys34 Thiol

While polysorbates are pro-oxidants (generating peroxides), HSA is a potent antioxidant.

• The Free Thiol: HSA contains a single free cysteine residue at position 34 (Cys34). This thiol group (-SH) constitutes the major reducing power of human plasma (Oettl & Stauber, 2007).
• Radical Scavenging: Cys34 actively scavenges Reactive Oxygen Species (ROS) such as hydrogen peroxide and superoxide. By intercepting these radicals, albumin acts as a “sacrificial antioxidant,” becoming oxidized itself (to sulfenic acid) to protect the high-value therapeutic cargo from oxidative damage (Taverna et al., 2013).

The Recombinant Advantage: InVitria’s rHSA

Historically, the use of HSA was limited by the risks of plasma-derived sources (viral transmission, supply inconsistency). The advent of high-purity recombinant HSA (rHSA) has eliminated these barriers.

Comparison: Plasma vs. Recombinant